TY - JOUR
T1 - Humoral Antibody Responses to HIV Viral Proteins and to CD4 among HIV Controllers, Rapid and Typical Progressors in an HIV-Positive Patient Cohort
AU - Fink, Elizabeth
AU - Fuller, Katherine
AU - Agan, Brian
AU - Berger, Edward A.
AU - Saphire, Andrew
AU - Quinnan, Gerald V.
AU - Elder, John H.
N1 - Funding Information:
The authors wish to acknowledge the assistance of Dr. Sonia Jain, under the auspices of the Bioinformatics and Modeling Core of the University of California San Diego Center for AIDS Research (P30 AI036214) for review of statistical analyses performed in this study. Support for this work (IDCRP-000-32) was provided in part by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense program executed through the Uniformed Services University of the Health Sciences. This project was funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072 (G.V.Q., B.A.) and by R21 AI100764 ( J.H.E.).
Publisher Copyright:
© Elizabeth Fink, et al., 2016; Published by Mary Ann Liebert, Inc. 2016.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - The purpose of this study was to assess humoral antibody responses as a function of disease progression (DP) in a well-defined HIV+ cohort. We quantified antibodies to HIV-1 gp120, Gag, and CD4 receptor by enzyme-linked immunosorbent assay in sera from a cohort of 97 HIV+ subjects at defined stages of DP. We also measured antibody-dependent cellular cytotoxicity (ADCC) as a function of the clinical status of the patients. We purified antibodies to CD4 and gp120 and assessed them for specificity, ability to block gp120 binding to target cells, ability to block virus infection, and ability to facilitate ADCC. All of the HIV+ patient samples were positive for antibodies to HIV gp120 and p24 and 80% showed evidence of hypergammaglobulinemia. Approximately 10% of cohort members were positive for antibodies to CD4, but we noted no significant correlation relevant to DP. There were statistically significant differences between the groups concerning the level of humoral response to gp120 and Gag. However, we observed no distinction in ability of anti-gp120 antibodies purified from each group to neutralize infection. In addition, there was a statistically significant difference in ADCC, with elite controllers exhibiting significantly lower levels of ADCC than the other five groups. We detected IgA anti-gp120 antibodies, but did not correlate their presence with either DP or ADCC levels. The results are consistent with the interpretation that the humoral antibody response to the antigens assessed here represents a signature of the level of viremia but does not correlate with clinical status of HIV infection.
AB - The purpose of this study was to assess humoral antibody responses as a function of disease progression (DP) in a well-defined HIV+ cohort. We quantified antibodies to HIV-1 gp120, Gag, and CD4 receptor by enzyme-linked immunosorbent assay in sera from a cohort of 97 HIV+ subjects at defined stages of DP. We also measured antibody-dependent cellular cytotoxicity (ADCC) as a function of the clinical status of the patients. We purified antibodies to CD4 and gp120 and assessed them for specificity, ability to block gp120 binding to target cells, ability to block virus infection, and ability to facilitate ADCC. All of the HIV+ patient samples were positive for antibodies to HIV gp120 and p24 and 80% showed evidence of hypergammaglobulinemia. Approximately 10% of cohort members were positive for antibodies to CD4, but we noted no significant correlation relevant to DP. There were statistically significant differences between the groups concerning the level of humoral response to gp120 and Gag. However, we observed no distinction in ability of anti-gp120 antibodies purified from each group to neutralize infection. In addition, there was a statistically significant difference in ADCC, with elite controllers exhibiting significantly lower levels of ADCC than the other five groups. We detected IgA anti-gp120 antibodies, but did not correlate their presence with either DP or ADCC levels. The results are consistent with the interpretation that the humoral antibody response to the antigens assessed here represents a signature of the level of viremia but does not correlate with clinical status of HIV infection.
KW - ADCC
KW - HIV
KW - HIV clinical outcomes research
KW - envelope
UR - http://www.scopus.com/inward/record.url?scp=85005992314&partnerID=8YFLogxK
U2 - 10.1089/aid.2016.0182
DO - 10.1089/aid.2016.0182
M3 - Article
C2 - 27771962
AN - SCOPUS:85005992314
SN - 0889-2229
VL - 32
SP - 1187
EP - 1197
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
IS - 12
ER -